Development of iPSC-derived immune cell-based cancer immunotherapy, from the aspect of non-clinical safety tests

Abstract

As an AMED supported project, we are developing cancer immunotherapy using immune cells derived from HLA haplotype-identical allogeneic iPS cells. Specifically, we are working on the development of iCAR-ILC / NK therapy using NK cells, which are classified as innate lymphoid cells. At this symposium, I would like to introduce the basics of iCAR-ILC / NK therapy and our efforts toward clinical trials including non-clinical safety tests.